Valbiotis raises €10.2M to scale its cardiometabolic health products
What's the deal? French laboratory Valbiotis has raised €10.2M in a post-IPO equity round to fund the commercial expansion of its range of natural healthcare products.
The La Rochelle-based company designs scientifically tested products to prevent cardiometabolic imbalances and address everyday health issues.
Backers included Singapore's Ximen RD PTE Ltd — owned by Chinese partner Xianhua Tao — and Avenir France PME, managed by Talence Patrival.
Why now? Valbiotis says it now has the resources to deliver on short-term ambitions in France and abroad.
The capital increase, structured with shareholders' pre-emptive subscription rights, drew demand for 7,204,512 new shares at €0.86 each — about 60.85% of the maximum on offer.
Guarantors covered the rest, taking up 4,635,488 shares worth roughly €4.0M to ensure the round closed in full.
The signal: A breakout-stage company tapping public markets rather than venture capital, Valbiotis is betting that proven science can carry it from the lab to the shelf — with its Chinese joint-venture partner Xianhua Tao underwriting a €2.0M commitment to anchor that commercial push at home and abroad.
Read more: EQS News
Image credit: nenad53
